Pyoderma gangrenosum
Pyoderma gangrenosum нь ховор тохиолддог үрэвсэлт арьсны өвчин бөгөөд өвдөлттэй идээт идээт эсвэл зангилаа нь аажмаар ургаж, шарх болж хувирдаг. Pyoderma gangrenosum нь халдварт биш юм. Эмчилгээнд кортикостероидууд, циклоспорин эсвэл янз бүрийн моноклональ эсрэгбие орно. Хэдийгээр энэ нь ямар ч насны хүмүүст тохиолдож болох ч ихэнхдээ 40-50 насны хүмүүст нөлөөлдөг.
☆ Германаас гаргасан 2022 оны Stiftung Warentest-ийн үр дүнгээс үзэхэд ModelDerm-ийн хэрэглэгчдийн сэтгэл ханамж нь төлбөртэй телемедицинийн зөвлөгөө авахаас арай доогуур байв.
Шархлаат колиттой хүний хөл дээр.
References
Pyoderma gangrenosum нь улаан эсвэл нил ягаан өнгийн ирмэгтэй өвдөлттэй шарх үүсгэдэг арьсны ховор өвчин юм. Энэ нь үрэвсэлт өвчин гэж ангилдаг бөгөөд нейтрофил дерматоз гэж нэрлэгддэг бүлгийн нэг хэсэг юм. Pyoderma gangrenosum -ийн шалтгаан нь нарийн төвөгтэй бөгөөд генетикийн хандлагатай хүмүүсийн төрөлхийн болон дасан зохицох дархлаатай холбоотой асуудлуудтай холбоотой байдаг. Сүүлийн үед судлаачид үсний уутанцарыг өвчний эхлэлийн цэг болгон анхаарч байна.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum нь маш их өвддөг шархлаа үүсгэдэг ховор арьсны өвчин юм. Бид түүний шалтгааныг бүрэн ойлгоогүй ч тодорхой дархлааны эсийн идэвхжил нэмэгддэг гэдгийг бид мэднэ. Өвчин эмчлэх нь тийм ч амар биш байна. Дархлааг дарангуйлдаг эсвэл үйл ажиллагааг нь өөрчилдөг янз бүрийн эмүүд байдаг. Эдгээрээс гадна бид шархыг эмчлэх, өвдөлтийг намдаахад анхаарлаа хандуулдаг. Кортикостероидууд болон циклоспорин нь ихэвчлэн эмчилгээний эхний сонголт байдаг боловч сүүлийн үед TNF-α дарангуйлагч зэрэг биологийн эмчилгээг ашиглах талаар илүү их судалгаа хийж байна. Эдгээр биологийн эмийг ялангуяа бусад үрэвсэлт өвчтэй өвчтөнүүдэд илүүд үздэг бөгөөд өвчний эхэн үед хэрэглэж байна.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
